Prescription of renin‐angiotensin‐aldosterone system inhibitors (RAASi) and its determinants in patients with advanced CKD under nephrologist care
Open Access
- 6 June 2019
- journal article
- research article
- Published by Wiley in The Journal of Clinical Hypertension
- Vol. 21 (7) , 991-1001
Abstract
Renin‐angiotensin‐aldosterone system inhibitors (RAASi) are recommended for chronic kidney disease (CKD) patients. In this study, we describe RAASi prescription patterns in the Chronic Kidney Disease Outcomes and Practice Patterns Study (CKDopps) in Brazil, Germany, France, and the United States (US). 5870 patients (mean age 66‐72 years; congestive heart failure [CHF] in 11%‐19%; diabetes in 43%‐54%; serum potassium ≥5 in 20%‐35%) were included. RAASi prescription was more common in Germany (80%) and France (77%) than Brazil (66%) and the United States (52%), where the prevalence of prescription decreases particularly in patients with CKD stage 5. In the multivariable regression model, RAASi prescription was least common in the United States and more common in patients who were younger, had diabetes, hypertension, or less advanced CKD. In conclusion, RAASi prescription patterns vary by country, and by demographic and clinical characteristics. RAASi appear to be underused, even among patients with strong class‐specific recommendations. Although the reasons for this variation could not be fully identified in this cross‐sectional observation, our data indicate that the risk of hyperkalemia may contribute to the underuse of this class of agents in moderate to advanced CKD.Keywords
Funding Information
- National Health and Medical Research Council
- Cancer Care Ontario
- Institut National de la Santé et de la Recherche Médicale
- Thailand Research Fund
- King Chulalongkorn Memorial Hospital
- National Research Council of Thailand
- National Institute for Health Research
- Agence Nationale de la Recherche
- Japan Agency for Medical Research and Development
This publication has 14 references indexed in Scilit:
- Treatment of Abnormalities of Potassium Homeostasis in CKDAdvances in Chronic Kidney Disease, 2017
- Antihypertensive medications and risk of death and hospitalizations in US hemodialysis patientsMedicine, 2017
- 2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of AmericaCirculation, 2016
- The CKD Outcomes and Practice Patterns Study (CKDopps): Rationale and MethodsAmerican Journal of Kidney Diseases, 2016
- Antihypertensive Medications and the Prevalence of Hyperkalemia in a Large Health SystemHypertension, 2016
- Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors.2015
- Influence of Nephrologist Care on Management and Outcomes in Adults with Chronic Kidney DiseaseJournal of General Internal Medicine, 2015
- Potassium Homeostasis and Renin-Angiotensin-Aldosterone System InhibitorsClinical Journal of the American Society of Nephrology, 2010
- ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: a post hoc analysis of the REIN trial results. Ramipril Efficacy in Nephropathy.2001
- The Effect of Angiotensin-Converting-Enzyme Inhibition on Diabetic NephropathyNew England Journal of Medicine, 1993